1. INTRODUCTION
===============

Bone metastasis is a frequent complication of cancer and has been found in 70%--85% of cancer patients at autopsy [@b1-co15-5-211]. Metastasis most often occurs in patients with primary breast, prostate, and lung tumours [@b2-co15-5-211]. Approximately 50%--75% of patients will require treatment for their metastatic bone pain with the aim of symptom palliation [@b3-co15-5-211]. Radiation therapy has been shown to relieve bone pain in approximately 80% of patients [@b4-co15-5-211].

The Brief Pain Inventory ([bpi]{.smallcaps}) is a multidimensional instrument that was originally developed in 1994 by Cleeland and Ryan [@b5-co15-5-211] to address the problem of inadequate pain control in cancer patients. The [bpi]{.smallcaps} is the most frequently used multiple-item measure of pain in cancer research [@b6-co15-5-211], and it is measured on the sensory and affective dimensions. The sensory component of pain intensity measures worst, average, and current pain, and the affective dimension of functional interference includes general activity, normal work (including work outside the home and housework), walking ability, mood, sleep, relations with others, and enjoyment of life. Previous research found that changes in worst pain are significantly correlated with 6 of the 7 life functions, "relations with others" being the exception [@b7-co15-5-211],[@b8-co15-5-211].

The term "symptom cluster" was first coined by Dodd, Miaskowski, and Paul in 2001 in their work with pain, fatigue, and sleep disturbances [@b9-co15-5-211]. Symptom clusters have been proposed to consist of at least 2 [@b10-co15-5-211] or 3 [@b9-co15-5-211] interrelated symptoms in a stable group that is relatively independent of other clusters and that possibly reveals specific underlying dimensions or mechanisms [@b10-co15-5-211]. Symptoms within a cluster may or may not have the same underlying cause [@b9-co15-5-211]. However, to be considered clustered, symptoms must have a stronger relationship with symptoms in the same cluster than with symptoms in other clusters [@b10-co15-5-211]. Because the [bpi]{.smallcaps} assesses pain on several dimensions, the present study defined a symptom cluster as 2 or more interrelated symptoms or functional interference items.

From May 2003 to January 2007, we conducted a previous study at the Odette Cancer Centre and, using the [bpi]{.smallcaps}, extracted 2 symptom clusters in patients receiving palliative radiation therapy ([rt]{.smallcaps}) for symptomatic bone pain [@b11-co15-5-211]. The 348 individuals who agreed to participate in the study completed the [bpi]{.smallcaps} before [rt]{.smallcaps} (baseline) and at weeks 4, 8, and 12 post [rt]{.smallcaps} [@b11-co15-5-211].

Two symptom clusters were identified at baseline:

-   An activity-related interference cluster (cluster 1)

-   A psychological-related interference cluster (cluster 2)

Cluster 1 consisted of worst pain and interference with normal work, general activity, walking ability, and enjoyment of life. Cluster 2 consisted of interference with relations with others, sleep, and mood. In responders to [rt]{.smallcaps}, no symptom clusters were identified in the follow-up assessments. However, in non-responders to radiation, symptom clusters appeared at week 8 post [rt]{.smallcaps}. Symptom clusters appear to be unstable, and so it is clinically important to validate reported symptom clusters found in previous research to determine if they hold true across similar patient populations.

The primary objective of the present study was to validate the findings from our previous study [@b11-co15-5-211] by comparing the extracted symptom clusters at baseline and at 4, 8, and 12 weeks post [rt]{.smallcaps}.

2. PATIENTS AND METHODS
=======================

The Rapid Response Radiotherapy Program ([rrrp]{.smallcaps}) at the Odette Cancer Centre is an innovative program that was initiated in 1996 to provide timely palliative [rt]{.smallcaps} for symptom relief in patients with advanced disease [@b12-co15-5-211]. The [rrrp]{.smallcaps} provides an opportunity for cancer patients to be assessed, planned, and treated on the day of first consultation so as to relieve symptomatic cancer pain and to maintain or improve quality of life.

All patients referred to the [rrrp]{.smallcaps} for palliative [rt]{.smallcaps} of symptomatic bone metastases were considered for this study. For study participation, patients had to be at least 18 years of age, to have radiologic evidence of bone metastases, and to provide informed consent. Patients were excluded if there was a language barrier or if they had experienced a pathologic fracture or spinal cord compression.

From February to September 2007, 52 patients from the [rrrp]{.smallcaps} were enrolled into the study. At initial consultation, patients with bone metastases were asked to rate their worst pain and functional interference scores on the [bpi]{.smallcaps} using 11-point numeric rating scales. The numeric rating scales had descriptive anchors of 0 for "no pain" or "does not interfere" and 10 for "worst imaginable pain" or "completely interferes."

All reference to pain was specific to the irradiated site in these patients. Patient demographics, which included age, sex, cancer history, Karnofsky performance status ( ) [@b13-co15-5-211] [kps]{.smallcaps} , and analgesic consumption during the preceding 24 hours were recorded at the first visit. Opioid analgesics were converted to total daily oral morphine equivalent doses. The progress of a patient's response to palliative [rt]{.smallcaps} was monitored using the [bpi]{.smallcaps} at 4, 8, and 12 weeks post [rt]{.smallcaps}. A research assistant was responsible for obtaining [bpi]{.smallcaps} scores in telephone interviews.

Patient confidentiality was maintained, and patients were assigned a unique number for study identification purposes. Ethical approval was obtained from the hospital research ethics board, and all questionnaire administration and information collection was performed by a trained research assistant. The entire process was consistent with the principles set out in the Declaration of Helsinki on conducting clinical research.

Our study defined responders to radiation treatment as patients experiencing a complete ([cr]{.smallcaps}) or partial response ([pr]{.smallcaps}). The International Bone Metastases Consensus Working Party [@b14-co15-5-211] defines "complete response" as a pain score of 0 at the irradiated site, with no concomitant increase in analgesic intake (stable or reduced analgesics in daily oral morphine equivalent doses). It defines "partial response" as a pain reduction of 2 points or more at the irradiated site on a 0--10 scale without analgesic increase or with an analgesic reduction of 25% or more from baseline without an increase in pain [@b14-co15-5-211].

2.1 Statistical Analyses
------------------------

Results are expressed as mean ± standard deviation or median and range for quantitative variables, and as proportions for categorical findings. The chi-square test was used to test for differences in the averages of symptom severity and of functional interference scores between the sexes. The Spearman correlation was applied at baseline to determine the strength of the correlation between any 2 of the 8 items.

Principal component analysis ([pca]{.smallcaps}) with varimax rotation was applied to worst pain and the 7 functional interference items. To determine relationships between items before and after [rt]{.smallcaps} for bone pain, [pca]{.smallcaps} was performed on the 8 items at each time point for responders and for non-responders alike.

The highest factor loading score predicted the assignment of individual symptoms to an independent factor. The Cronbach alpha statistic was used to estimate the internal consistency and reliability of the derived clusters at baseline and at subsequent follow-ups. Using a biplot graphic, robust relationships and correlations between the 8 items were displayed; the length and proximity of arrows acted as determinants of the strength of the correlations. The final communality refers to the percentage variance in an observed variable that was accounted for by the retained clusters.

A general linear mixed model was used to determine whether the [bpi]{.smallcaps} items changed over time (from baseline to week 12) in all patients and whether a responder effect occurred over time (from week 4 to week 12). Results were considered significant at the 5% critical level (*p* \< 0.05). All calculations were performed using the [sas]{.smallcaps} (version 9.1: SAS Institute, Cary, NC, U.S.A.) and [s]{.smallcaps}-[plus]{.smallcaps} (version 7.0: Mathsoft, Cambridge, MA, U.S.A.) statistical software packages.

3. RESULTS
==========

From February to September 2007, our study accrued 52 patients with symptomatic bone metastases \[29 men (55.8%), 23 women (44.2%); median age: 68.5 years (range: 39--87 years)\] who received [rt]{.smallcaps}. All participants provided complete baseline data at initial consultation. [Table [I]{.smallcaps}](#tI-co15-5-211){ref-type="table"} summarizes patient demographics and disease information. These patients had a median [kps]{.smallcaps} of 70 (range: 40--90) and a median daily morphine equivalent dose of 10 mg. Prostate (30.8%), breast (28.9%), and lung (19.2%) were the most common primary cancer sites. Most patients received a single fraction of 8 Gy to the spine.

[Table II](#tII-co15-5-211){ref-type="table"} lists the prevalences, sex differences, and median severities for "worst pain" and the 7 functional interference items. A symptom was considered present if it was scored greater than 0. All 52 patients had a "worst pain" score.

The 3 most prevalent interference items were general activity (88.2%), enjoyment of life (88.0%), and normal work (85.7%). For individuals who were experiencing interference, all 8 items had a moderate-to-severe functional median severity score, with normal work being the highest (median score: 8). In using chi-square analyses to test for sex differences, we observed no significant difference between women and men on any [bpi]{.smallcaps} item except for relations with others (*p* = 0.029).

Before [rt]{.smallcaps}, some of the patients did not experience certain functional interference items. For those who provided a score, [Table III](#tIII-co15-5-211){ref-type="table"} lists the symptom distress of patient-assessed worst pain and of functional interference scores. The median symptom distress ranged from 3.5 to 7 for the 8 items. "Worst pain" and "normal work" had the highest symptom distress, with "relations with others" ranking lowest.

The Spearman correlations in [Table IV](#tIV-co15-5-211){ref-type="table"} depict the strength of the relationships between the 8 items. Each Spearman correlation was highly significant (*p* \< 0.0001), except for the relationships of sleep with pain (*p* = 0.0008), with general activity (*p* = 0.0004), with walking ability (*p* = 0.0068), and with relations with others (*p* = 0.0029). Other nonsignificant Spearman correlations were observed for enjoyment of life with walking ability (*p* = 0.0014) and with normal work (*p* = 0.0003), and for relations with others with normal work (*p* = 0.0015). Correlations between items ranged from 0.38 to 0.88, with the lowest correlation occurring between sleep and walking ability, and the highest correlation occurring between normal work and general activity.

The [pca]{.smallcaps} with varimax rotation extracted principal components with a minimum Eigenvalue of 0.75 that each explained more than 10% of the total variance. Two components or symptom clusters were extracted from the questionnaire completed before [rt]{.smallcaps}, accounting for 77% of the total variance.

Cluster 1 included walking ability, general activity, normal work, and worst pain; it accounted for 67% of the total variance. Cluster 2 included relations with others, enjoyment of life, mood, and sleep; it accounted for 10% of the total variance. Using the Cronbach alpha, the internal reliabilities of the two clusters were high at 0.85 in cluster 2 and 0.92 in cluster 1, demonstrating good internal consistency ([Table V](#tV-co15-5-211){ref-type="table"}). The final communalities showed that all the variables were well accounted for by the two clusters, with final communality estimates ranging from 0.57 for sleep to 0.93 for general activity. [Figure 1](#f1-co15-5-211){ref-type="fig"} shows a biplot for the two principal components, cluster 1 and cluster 2, depicting a two-dimensional model. The two clusters are distinct, being that they have different orientations. The arrows of longer length and closer proximity suggest a higher correlation between symptoms.

Because of attrition, follow-up response rates at weeks 4, 8, and 12 were respectively 41.2%, 35.0%, and 23.8% of the 52 patients. Using a general linear mixed model, all worst pain and functional interference scores significantly decreased over time (*p* \< 0.0001), except for mood (*p* = 0.0002) and relations with others (*p* = 0.0047, [Table VI](#tVI-co15-5-211){ref-type="table"}). However, total oral morphine equivalent dose did not display a significant change from baseline to week 12 (*p* = 0.8091, [Table VI](#tVI-co15-5-211){ref-type="table"}).

The percentages of patients who responded to [rt]{.smallcaps} throughout the follow-up assessments were 60.1% at week 4, 67.9% at week 8, and 73.7% at week 12. [Table VII](#tVII-co15-5-211){ref-type="table"} sets out the number of patients at each time point and the proportion that had a [cr]{.smallcaps} or [pr]{.smallcaps} to [rt]{.smallcaps}.

Because of the small sample size in the responder and non-responder groups alike, we decided not to run the [pca]{.smallcaps} to extract symptom clusters. Any symptom clusters extracted would not be reliable from a statistical viewpoint. [Table VIII](#tVIII-co15-5-211){ref-type="table"} summarizes the symptom cluster dynamics throughout the duration of the study. In keeping with the criteria of extracting symptom clusters with a minimum Eigenvalue of 0.75 and a minimum proportion of variance of 10%, 2 clusters could be extracted at baseline, at week 4, and at week 8. However, these clusters did not remain consistent over time; they varied at each time point. The functional interference items that clustered consistently were walking ability and general activity in cluster 1 and relations with others and mood in cluster 2. The pair of items in cluster 2 clustered together with those found in cluster 1 after the initiation of [rt]{.smallcaps} in weeks 4 and 8. At week 12, no symptom clusters that met the symptom cluster criteria could be identified.

4. DISCUSSION
=============

Our findings on clusters match the two factors extracted in a Norwegian validation study of the [bpi]{.smallcaps} [@b15-co15-5-211]. Klepstad and colleagues performed a principal factor analysis with direct oblimin solution on a sample of 300 hospitalized cancer patients \[55% men; median age: 63 years; median [kps]{.smallcaps}: 70 (range: 10--90)\] [@b15-co15-5-211]. The most common primary cancer sites were breast (20%), prostate (20%), and lung (18%). Confirmed metastatic disease was diagnosed in 235 patients. Klepstad *et al.* were able to extract 2 factors: interference with physical function (general activity, walking ability, and normal work), and interference with psychological function (mood, relations with others, sleep, and enjoyment of life) [@b15-co15-5-211]. A third factor of pain severity was extracted in the Norwegian study, which included worst, least, average, and current pain. However, only worst pain was included in our study's analysis. Consequently, worst pain compounded the activity-related interference found in our initial symptom cluster research in cancer patients with metastatic bone pain [@b11-co15-5-211].

The findings in the present validation study differ slightly from our initial symptom cluster research [@b11-co15-5-211]. We extracted 2 symptom clusters before [rt]{.smallcaps} start, calling cluster 1 "activity-related interference" and cluster 2 "psychology-related interference." These clusters were reproducible at baseline in the current validation study; however, in the previous study, enjoyment of life was more highly correlated with the activity-related interference items and compounded cluster 1 (activity-related interference) [@b11-co15-5-211].

The initial findings in our previous study showed that the statistical analysis failed to extract any symptom clusters in the responder group after initiation of [rt]{.smallcaps}[@b11-co15-5-211]. The symptom clusters had dispersed at weeks 4, 8, and 12, and no cluster could be extracted with further statistical analysis (that is, [pca]{.smallcaps}). The disintegration of the symptom clusters was attributed to the alleviation of symptomatic bone pain, which thus had a direct influence on the functional interference in all 7 items. The dynamics of the symptom clusters in the responders showed that all items were affected, thus further supporting the validity of the [bpi]{.smallcaps} [@b5-co15-5-211].

The current validation study was able to extract 2 symptom clusters at weeks 4 and 8, and yet it failed to extract any symptom clusters in week 12 of the follow-up assessments. Although 2 symptom clusters were observed, these clusters varied at each time point. The items rearranged themselves to cluster with different items in weeks 4 and 8.

Among the 8 items, walking ability and general activity consistently remained together in cluster 1 (activity-related interference). The consistency for this pair of items is evidence of a common underlying construct, which supports the theory developed by Kim *et al.* in 2005 [@b10-co15-5-211]. (Walking ability and general activity both involve considerable physical activity of the lower limbs.) On the other hand, relations with others and mood consistently remained together, yet transferred from cluster 2 (psychology-related interference) at baseline to cluster 1 (activity-related interference) in weeks 4 and 8. The influence of pain on psychological symptoms may be related to a combination of physical suffering and a patient's interpretation of pain in the context of malignant disease.

At baseline, the 2 symptom clusters of activity-related and psychology-related interference in the present study differ slightly from those seen in the previous symptom cluster study [@b11-co15-5-211]. In the present research, enjoyment of life had a stronger correlation with psychology-related interference items than with activity-related interference items (as in the past). We also observed that "worst pain" had a higher correlation with walking ability and general activity in cluster 1 and therefore remained with these items at week 4. Interestingly, "worst pain" clustered out of cluster 1 (activity-related interference) at week 4 and showed a stronger correlation with interference with sleep in cluster 2 at week 8 ([Table VIII](#tVIII-co15-5-211){ref-type="table"}). We are unable to explain why a patient's worst pain would cluster with a subdued or inactive state of sleeping than with a state that requires vigorous activity and stress on a patient's body, such as walking ability, general activity, and normal work.

Symptom clusters are a dynamic construct and remain unpredictable across varied treatments, conditions, and time periods. This symptom cluster phenomenon is not limited to the present research, but has also been observed in earlier studies with symptom clusters [@b16-co15-5-211],[@b17-co15-5-211]. Using the Edmonton Symptom Assessment Scale on patients with bone [@b16-co15-5-211] and brain metastases [@b17-co15-5-211], these two studies were able to extract symptom clusters at baseline that rearranged at subsequent follow-up weeks. Certain clusters changed after [rt]{.smallcaps}; others remained stable. As a result, the findings in our present study are not unexpected.

Kirkova and Walsh [@b18-co15-5-211] refined the term "cluster stability" in an editorial published in *Supportive Care in Cancer.* They defined cluster stability as a cluster composition across subjects and time. It can be conceptualized as specific clusters that exist in a variety of patient populations or those influenced by a common intervention.

Symptom clusters are a dynamic construct and are influenced by a specific symptom, its severity, treatment, primary cancer site, stage of disease, and symptom meaning [@b19-co15-5-211]--[@b21-co15-5-211]. Bone metastases may have a different meaning to the patient at different times during the disease trajectory [@b18-co15-5-211]. This difference may explain the variation of symptom clusters in the present study from baseline to weeks 4 and 8.

In comparing the present validation study to the previous study conducted in 2007, we observed that patients in the 2007 group had higher median "worst pain" and functional interference (specifically, general activity, walking ability, and enjoyment of life) scores. They had less interference with relations with others. Median scores for mood and sleep interference were identical in both studies. The severity of an individual's bone pain symptoms may determine greater cluster variability [@b18-co15-5-211]. Our study did not test for significance, but the differences in median score may account for the cluster instability across the two studies.

4.1 Limitations
---------------

The differences between the two studies may be attributable to the lesser number of patients in the present validation study. A sample size of 52 patients is significantly less than a population of 348 patients.

Comparisons between symptom cluster studies remain difficult. The variations in cluster composition are a direct result of the measurement instrument, the study methodology, the statistical analysis, and the cutoff points used to determine a symptom cluster [@b22-co15-5-211]--[@b24-co15-5-211]. Comparisons also remain an obstacle because no consensus has yet been reached concerning the definition of a symptom cluster and the clinical meaning of a derived cluster.

The present validation study adds to the exploration and further understanding of symptom cluster dynamics and the possible instability of symptom clusters over time and over subjects. Symptom cluster research is still being refined, but it may eventually facilitate diagnosis and treatment follow-up, and may aid in predicting survival in clinical practice [@b18-co15-5-211].

An additional validation study with a larger patient population is highly recommended. The sample size in the present study was not large enough to produce reliable results. To rule out the phenomenon of cluster instability, more studies must be conducted using the same methodology of extracting symptom clusters: for example, use of a standard instrument; similar patient populations; identical definitions, criteria, and cut-off points; and repeated assessments at appropriate time intervals.

5. CONCLUSIONS
==============

The refinement of definitions, development of criteria, and determination of optimal statistical methods could help to develop symptom cluster research standards and, hopefully, to identify clinically important clusters [@b18-co15-5-211].

Following verification of a symptom cluster, subsequent research has to determine whether that cluster occurs in other patient samples and whether it constitutes a "symptom cluster diagnosis" [@b18-co15-5-211]. The same study should be repeated in patient samples other than a bone metastases group to see whether similar symptom clusters can be extracted on the basis of cancer-related pain in general.

6\. ACKNOWLEDGMENT

This project is generously supported by the Michael and Karen Goldstein Cancer Research Fund.

![Biplot between components 1 and 2.](co15-5-211f1){#f1-co15-5-211}

###### 

Patient characteristics

  Characteristic                      Value
  ----------------------------------- ---------------
  Patients (*n*)                      52
  Sex \[*n* (%)\]                     
   Male                               29 (55.8)
   Female                             23 (44.2)
  Age at radiation (years)            
   Mean ± SD                          66.9±11.6
   Median (range)                     68.5 (39--87)
  Karnofsky performance status        
   Mean ± SD                          70.2±12.8
   Median (range)                     70 (40--90)
  Total morphine equivalent (mg)      
   Mean ± SD                          77.6±163
   Median (range)                     10 (0--880)
  Primary cancer sites \[*n* (%)\]    
   Prostate                           16 (30.8)
   Breast                             15 (28.9)
   Lung                               10 (19.2)
   Bladder                            4 (7.7)
   Pancreas/gastric                   3 (5.8)
   Others                             4 (7.7)
  Sites of radiotherapy \[*n* (%)\]   
   Spine                              22 (42.3)
   Hips                               9 (17.3)
   Pelvis                             7 (13.5)
   Shoulders                          5 (9.6)
   Rib or ribs                        4 (7.7)
   Extremities                        2 (3.8)
   Other                              3 (5.8)
  Radiation dose \[*n* (%)\]          
   800 cGy/1 fraction                 40 (76.9)
   2000 cGy/5 fractions               11 (21.2)
   3000 cGy/10 fractions              1 (1.9)

SD = standard deviation.

###### 

Prevalence, sex difference, and median severity of worst pain and 7 functional interference items

  Symptom                 Functional prevalence   Functional severity [a](#tfn2-co15-5-211){ref-type="table-fn"}                                   
  ----------------------- ----------------------- ---------------------------------------------------------------- ----------- ----------- ------- -----------
  Worst pain              52                      52 (100)                                                         29 (100)    23 (100)    0.999   7 (1--10)
  General activity        51                      45 (88.2)                                                        24 (85.7)   21 (91.3)   0.523   7 (2--10)
  Enjoyment of life       50                      44 (88.0)                                                        25 (92.6)   19 (82.6)   0.279   7 (1--10)
  Normal work             42                      36 (85.7)                                                        18 (85.7)   18 (85.7)   0.999   8 (2--10)
  Walking ability         50                      40 (80.0)                                                        21 (77.8)   19 (82.6)   0.670   7 (2--10)
  Mood                    51                      40 (78.4)                                                        22 (78.6)   18 (78.3)   0.979   7 (1--10)
  Sleep                   51                      40 (78.4)                                                        20 (71.4)   20 (87.0)   0.180   6 (1--10)
  Relations with others   50                      31 (62.0)                                                        13 (48.2)   18 (78.3)   0.029   6 (1--10)

Functional severity in patients who scored greater than zero. 1 = minimum functional severity; 10 = worst possible functional severity.

Sex difference as compared by chi-square test. "Total" is all patients who scored the item. "Overall" is all patients who scored the item as greater than 0.

###### 

Worst pain scores and functional interference items at baseline (scale: 0--10)

  Symptom                 Patients (n)   Mean *± SD*   Median (range)
  ----------------------- -------------- ------------- ----------------
  Worst pain              52             6.50±2.57     7 (1--10)
  Normal work             42             6.24±3.46     7 (0--10)
  General activity        51             5.90±3.20     6 (0--10)
  Enjoyment of life       50             5.74±2.96     6 (0--10)
  Walking ability         50             5.62±3.58     6 (0--10)
  Mood                    51             4.92±3.58     5 (0--10)
  Sleep                   51             4.90±3.61     5 (0--10)
  Relations with others   50             3.60±3.48     3.5 (0--10)

SD = standard deviation.

###### 

Spearman correlation among worst pain and functional interference items at baseline

  Items                   Worst pain   General activity   Mood   Walking ability   Normal work   Relations with others   Sleep   Enjoyment of life
  ----------------------- ------------ ------------------ ------ ----------------- ------------- ----------------------- ------- -------------------
  Worst pain              1                                                                                                      
  General activity        0.65         1                                                                                         
  Mood                    0.66         0.77               1                                                                      
  Walking ability         0.56         0.80               0.60   1                                                               
  Normal work             0.61         0.88               0.67   0.72              1                                             
  Relations with others   0.58         0.62               0.70   0.58              0.48          1                               
  Sleep                   0.45         0.48               0.57   0.38              0.57          0.41                    1       
  Enjoyment of life       0.59         0.59               0.62   0.44              0.53          0.58                    0.55    1

*p* Value of Spearman correlation is highly significant (\<0.0001) between items, except for sleep with worst pain (*p* = 0.0008), with general activity (*p* = 0.0004), with walking ability (*p* = 0.0068), and with relations with others (*p* = 0.0029); enjoyment of life with walking ability (*p* = 0.0014) and with normal work (*p* = 0.0003); and relations with others with normal work (*p* = 0.0015).

###### 

Factor loadings and final communality from the principal component analysis

                          Component[a](#tfn6-co15-5-211){ref-type="table-fn"}              
  ----------------------- ----------------------------------------------------- ---------- ------
  Walking ability         **0.86**                                              0.25       0.81
  General activity        **0.86**                                              0.44       0.93
  Normal work             **0.84**                                              0.36       0.84
  Worst pain              **0.64**                                              0.59       0.75
  Relations with others   0.21                                                  **0.82**   0.73
  Enjoyment of life       0.32                                                  **0.80**   0.75
  Mood                    0.48                                                  **0.76**   0.80
  Sleep                   0.39                                                  **0.65**   0.57
  Variance (%)            67                                                    10         
  Cronbach alpha          0.92                                                  0.85       

Boldface indicates a relationship between the functional interference items in each component.

###### 

Distress scores of worst pain and functional interference items of all patients (Pts) over time [a](#tfn7-co15-5-211){ref-type="table-fn"}

  Item                        Baseline   Week 4            Week 8   Week 12                                       
  --------------------------- ---------- ----------------- -------- ------------------ ---- ---------------- ---- ----------------
  Worst pain                  52         6.5±2.6 (7)       33       3.7±3.2 (4)        28   2.6±3.3 (0.5)    19   3.1±3.3 (2)
  General activity            51         5.9±3.2 (6)       31       3.7±3.8 (3)        27   2.6±3.4 (0)      19   2.7±3.2 (0)
  Mood                        51         4.9±3.6 (5)       32       3.4±3.8 (1.5)      28   2.0±3.2 (0)      19   2.2±3.0 (0)
  Walking ability             50         5.6±3.6 (6)       32       3.5±3.5 (2.5)      28   2.6±3.5 (0)      19   2.8±3.7 (1)
  Normal work                 42         6.2±3.5 (7)       29       3.9±4.0 (3)        27   2.9±3.9 (0)      19   3.1±3.8 (2)
  Relations with others       50         3.6±3.5 (3.5)     32       2.0±3.1 (0)        28   1.8±3.2 (0)      19   1.8±2.6 (0)
  Sleep                       51         4.9±3.6 (5)       31       2.8±3.1 (1)        27   1.8±3.0 (0)      19   1.8±2.9 (0)
  Enjoyment of life           50         5.7±3.0 (6)       32       3.8±3.6 (3.5)      28   2.6±3.4 (0.5)    19   2.6±3.0 (2)
  Total morphine equivalent   49         77.6±163.4 (10)   30       88.8±134.3 (3.5)   27   47.9±123.7 (0)   16   54.2±135.0 (0)

Using a general linear mixed model, all pain and functional item scores decreased significantly over time (*p* \< 0.0001), except for mood (*p* = 0.0002) and relations with others (*p* = 0.0047). However, total oral morphine equivalent dose did not present a significant change over time (*p* = 0.8091).

SD = standard deviation.

###### 

Response rates

                                                                             At 4 weeks   At 8 weeks   At 12 weeks
  -------------------------------------------------------------------------- ------------ ------------ -------------
  Patients (*n*)                                                             33           28           19
  Complete response [a](#tfn9-co15-5-211){ref-type="table-fn"} \[*n* (%)\]   9 (27.3)     12 (42.9)    5 (26.3)
  Partial response [a](#tfn9-co15-5-211){ref-type="table-fn"} \[*n* (%)\]    11 (33.3)    7 (25.0)     9 (47.4)
  Responders \[*n* (%)\]                                                     20 (60.1)    19 (67.9)    14 (73.7)
  Non-responders \[*n* (%)\]                                                 13 (39.4)    9 (32.1)     5 (26.3)

Complete and partial responses were defined as set out by the International Consensus of Bone Metastases Consensus Working Party on palliative radiotherapy endpoints [@b14-co15-5-211].

###### 

Summary of symptom cluster changes from baseline to subsequent follow-ups in all patients at each time point

  Statistics                    Value   Items [a](#tfn10-co15-5-211){ref-type="table-fn"}
  ----------------------------- ------- --------------------------------------------------------------------------------------------------------
  **At baseline**                       
  Min. Eigenvalue               0.77    
  Min. proportion of variance   10%     
  Cronbach alpha, cluster 1     0.92    Worst pain, **walking ability, general activity,** normal work
  Cronbach alpha, cluster 2     0.85    **Relations with others, mood,** enjoyment of life, sleep
  **At week 4**                         
  Min. Eigenvalue               0.86    
  Min. proportion of variance   11%     
  Cronbach alpha, cluster 1     0.95    Worst pain, **walking ability, general activity, relations with others, mood**
  Cronbach alpha, cluster 2     0.84    Normal work, sleep, enjoyment of life
  **At week 8**                         
  Min. Eigenvalue               0.85    
  Min. proportion of variance   11%     
  Cronbach alpha, cluster 1     0.96    **Walking ability, general activity,** normal work, **relations with others, mood,** enjoyment of life
  Cronbach alpha, cluster 2     0.77    Worst pain, sleep
  **At week 12**                        
  Min. Eigenvalue               0.44    
  Min. proportion of variance   5%      
  No clusters                           

Boldface indicates the items that consistently clustered together despite the movement between clusters.
